StockData
Design Therapeutics, Inc. logo

Design Therapeutics, Inc. (DSGN) stock

DSGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/30
$9.47−0.37 (-3.76%)

Close on Nov 18, 2026Market cap $592.65MP/E –Yield –

Design Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Design Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$55.14M. For fiscal 2025 it was -$54.55M. The highest annual figure on record is -$8.75M in fiscal 2020.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$54.55M–
FY2024Dec 31, 2024-$43.45M–
FY2023Dec 31, 2023-$58.82M–
FY2022Dec 31, 2022-$52.24M–
FY2021Dec 31, 2021-$30.92M–
FY2020Dec 31, 2020-$8.75M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$15.55M–
Q1 FY2026Mar 31, 2026-$16.43M–
Q4 FY2025Dec 31, 2025-$12.00M–
Q3 FY2025Sep 30, 2025-$11.16M–
Q2 FY2025Jun 30, 2025-$14.53M–
Q1 FY2025Mar 31, 2025-$16.86M–
Q4 FY2024Dec 31, 2024-$9.86M–
Q3 FY2024Sep 30, 2024-$9.53M–
Q2 FY2024Jun 30, 2024-$11.42M–
Q1 FY2024Mar 31, 2024-$12.63M–
Q4 FY2023Dec 31, 2023-$12.83M–
Q3 FY2023Sep 30, 2023-$14.59M–
Q2 FY2023Jun 30, 2023-$13.89M–
Q1 FY2023Mar 31, 2023-$17.51M–
Q4 FY2022Dec 31, 2022-$15.38M–
Q3 FY2022Sep 30, 2022-$14.21M–
Q2 FY2022Jun 30, 2022-$10.74M–
Q1 FY2022Mar 31, 2022-$11.90M–
Q4 FY2021Dec 31, 2021-$9.58M–
Q3 FY2021Sep 30, 2021-$9.13M–
Q2 FY2021Jun 30, 2021-$8.47M–
Q1 FY2021Mar 31, 2021-$3.73M–
Q4 FY2020Dec 31, 2020-$2.86M–

More Design Therapeutics figures

See a number that looks wrong?